nausea
Jump to navigation
Jump to search
Introduction
An unpleasant, but not painful sensation generally perceived in the upper abdomen.
It is generally accompanied by hypersalivation & the desire to vomit or the feeling that vomiting is imminent.
It may be brief, prolonged & sometimes occurs in waves.
See vomiting.
Etiology
- gut wall dilation -constipation, bowel obstruction, ileus (GUT)*
- gut mucosal injury
- radiation therapy, chemotherapy, infection, inflammation (gastritis), direct tumor invasion (GUT)*
- drugs, metabolites, bacterial toxins (CTZ)*
- new narcotic use is a likely cause of nausea
- motion sickess, labyrinthine disorders (vesibular)*
- anticipatory nausea (cerebral cortex)*
- increased intracranial pressure (?)*
* see pathology for mechanism at site or origin
Pathology
- mediated by
- dopamine D2 receptors or 5-HT3 receptors in GI tract
- dopamine D2 receptors, 5-HT3 receptors or neurokinin-1 receptors in the chemoreceptor trigger zone (CTZ)
- histamine H1 receptors & muscarinic receptors in the vestibular system
- unknown mediators in the cerebral cortex (putative)
Management
- sucking of hard candy or popsicle especially in children
- anticholinergics for motion sickness - scopolamine
- antihistamines - inner ear dysfunction or motion sickness
- dimenhydrinate (Dramamine) 50 mg PO/IV/IM every 4 hours
- promethazine (Phenergan) 25-50 mg PO/IV/IM every 4-6 hours
- dopaminergic antagonist (metochlopramide, prochlorperazine, haloperidol) for dopamine D2 receptor mediated nausea
- antacids for nausea due to gastritis[2]
- serotonin antagonists (ondansetron, granisetron) for 5-HT3 receptor (chemotherapy) mediated nausea
- aprepitant for resistant chemotherapy-induced nausea[2]
- benzodiazepines for anticipitory nausea
- glucocorticoids for increased intracranial pressure
- octreotide for nausea due to bowel obstruction
- do not use topical agents for treatment of nausea[2]
- treatment of nausea in palliative care
- if due to constipation, bowel obstruction, ileus
- dopaminergic antagonists
- metoclopramide, prochlorperazine, haloperidol, olanzapine
- olanzapine improves chronic nausea in patients with advanced incurable cancer[3][4]
- dopaminergic antagonists
- if due to chemotherapy, radiation, inflammation, advanced incurable cancer
- ondansetron, granisetron
- if intractable nausea & vomiting use ondanstetron 4 mg every 8 hours around the clock[2]
- ondansetron contraindicated wiht allergy to another 5-HT3 antagonist. i.e. alosetron
- if due to drugs, metabolites, bacterial toxins
- dopaminergic antagonists, glucocorticoids, serotonin receptor antagonists
- neurokinin-1 receptor antagonists: aprepitant, netupitant
- aprepitant relies on CYP3A4 metabolism as does oxycodone
- if due to labyrinthine disorder, motion sickness
- anticholinergic agents: scopolamine, diphenhydraine, promethazine
- increased intracranial pressure: glucocorticoids
- if due to constipation, bowel obstruction, ileus
- also see vomiting
More general terms
More specific terms
Additional terms
References
- ↑ Harrison's Principles of Internal Medicine, 13th ed. Companion Handbook, Isselbacher et al (eds), McGraw-Hill Inc. NY, 1995, pg 829-39
- ↑ 2.0 2.1 2.2 2.3 2.4 Geriatric Review Syllabus, 9th edition (GRS9) Medinal-Walpole A, Pacala JT, Porter JF (eds) American Geriatrics Society, 2016
Geriatric Review Syllabus, 11th edition (GRS11) Harper GM, Lyons WL, Potter JF (eds) American Geriatrics Society, 2022 - ↑ 3.0 3.1 Medical Knowledge Self Assessment Program (MKSAP) 20 American College of Physicians, Philadelphia 2025
- ↑ 4.0 4.1 Navari RM, Pywell CM, Le-Rademacher JG, et al. Olanzapine for the treatment of advanced cancer-related chronic nausea and/or vomiting: a randomized pilot trial. JAMA Oncol. 2020;6:895-899. PMID: https://pubmed.ncbi.nlm.nih.gov/32379269
- ↑ Moorthy GS, Letizia M. The Management of Nausea at the End of Life. J Hosp Palliat Nurs. 2018 Oct;20(5):442-449. PMID: https://pubmed.ncbi.nlm.nih.gov/30188436